Stadtmauer, E. A., Elghawy, O., Roberts, T. F., Madduri, D., Ailawadhi, S., Royal, M., & Yan, Y. (2023). SOR-CART-MM-001 Study: A Phase I, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Blood, 142(Supplement 1), 6851. https://doi.org/10.1182/blood-2023-178636

Stadtmauer, Edward A., Omar Elghawy, Todd F. Roberts, Deepu Madduri, Sikander Ailawadhi, Mike Royal, and Ying Yan. "SOR-CART-MM-001 Study: A Phase I, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)." Blood 142, no. Supplement 1 (2023): 6851. https://doi.org/10.1182/blood-2023-178636.

Stadtmauer, Edward A., et al. "SOR-CART-MM-001 Study: A Phase I, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)." Blood, vol. 142, no. Supplement 1, 2023, p. 6851, https://doi.org/10.1182/blood-2023-178636.